197 related articles for article (PubMed ID: 34349239)
1. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
2. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
[TBL] [Abstract][Full Text] [Related]
3. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.
Zhen S; Lu J; Liu YH; Chen W; Li X
Cancer Gene Ther; 2020 Apr; 27(3-4):168-178. PubMed ID: 31455836
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
6. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
[TBL] [Abstract][Full Text] [Related]
7. CUL2 overexpression driven by CUL2/E2F1/miR-424 regulatory loop promotes HPV16 E7 induced cervical carcinogenesis.
Xu J; Fang Y; Wang X; Wang F; Tian Q; Li Y; Xie X; Cheng X; Lu W
Oncotarget; 2016 May; 7(21):31520-33. PubMed ID: 27153550
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
9. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
10. Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.
Cheng YX; Chen GT; Yang X; Wang YQ; Hong L
Curr Med Sci; 2018 Apr; 38(2):212-221. PubMed ID: 30074178
[TBL] [Abstract][Full Text] [Related]
11. E7-Targeted Nanotherapeutics for Key HPV Afflicted Cervical Lesions by Employing CRISPR/Cas9 and Poly (Beta-Amino Ester).
Xiong J; Tan S; Yu L; Shen H; Qu S; Zhang C; Ren C; Zhu D; Wang H
Int J Nanomedicine; 2021; 16():7609-7622. PubMed ID: 34819726
[TBL] [Abstract][Full Text] [Related]
12. Sustained expression of HPV16 E7 oncoprotein promotes p-AKT(Ser473)/p-Src(Tyr527) signaling to drive precancerous lesions to invasive cervical cancer.
Lin Z; Zhao Y; Li Q; Ci X; Ye X; Chen G; Tu Q; Feng W; Jiang P; Zhu S; Xue X; Saunders NA; Zhang L; Zhu X; Zhao KN
Carcinogenesis; 2022 Jun; 43(5):479-493. PubMed ID: 35134836
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
Jubair L; Lam AK; Fallaha S; McMillan NAJ
PLoS One; 2021; 16(1):e0223288. PubMed ID: 33411765
[TBL] [Abstract][Full Text] [Related]
14. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells.
Hu Z; Yu L; Zhu D; Ding W; Wang X; Zhang C; Wang L; Jiang X; Shen H; He D; Li K; Xi L; Ma D; Wang H
Biomed Res Int; 2014; 2014():612823. PubMed ID: 25136604
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles Based on Poly (β-Amino Ester) and HPV16-Targeting CRISPR/shRNA as Potential Drugs for HPV16-Related Cervical Malignancy.
Zhu D; Shen H; Tan S; Hu Z; Wang L; Yu L; Tian X; Ding W; Ren C; Gao C; Cheng J; Deng M; Liu R; Hu J; Xi L; Wu P; Zhang Z; Ma D; Wang H
Mol Ther; 2018 Oct; 26(10):2443-2455. PubMed ID: 30241742
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic Human Papillomavirus: Application of CRISPR/Cas9 Therapeutic Strategies for Cervical Cancer.
Zhen S; Li X
Cell Physiol Biochem; 2017; 44(6):2455-2466. PubMed ID: 29268281
[TBL] [Abstract][Full Text] [Related]
17. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
18. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
19. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
20. Depletion of HPV16 early genes induces autophagy and senescence in a cervical carcinogenesis model, regardless of viral physical state.
Hanning JE; Saini HK; Murray MJ; Caffarel MM; van Dongen S; Ward D; Barker EM; Scarpini CG; Groves IJ; Stanley MA; Enright AJ; Pett MR; Coleman N
J Pathol; 2013 Nov; 231(3):354-66. PubMed ID: 23913724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]